Epizyme Inc (OQ:EPZM)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 400 Technology Sq Ste 4
CAMBRIDGE MA 02139-3584
Tel: N/A
Website: www.epizyme.com
IR: See website
Key People
David M. Mott
Independent Chairman of the Board
Robert B. Bazemore
President, Chief Executive Officer, Director
Paolo Tombesi
Chief Financial Officer
Jeffery L. Kutok
Chief Scientific Officer
Shefali Agarwal
Chief Medical Officer
Matthew E. Ros
Chief Strategy and Business Officer
Business Overview
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
Financial Overview
For the three months ended 31 March 2020, Epizyme Inc revenues decreased 83% to $1.4M. Net loss applicable to common stockholders increased 58% to $50.9M. Revenues reflect Collaboration revenue decrease of 99% to $70K. Higher net loss reflects General and administrative - Balancing increase from $9.9M to $22.6M (expense), Stock-based Compensation in SGA increase from $2M to $4.3M (expense).
Employees: 203 as of Feb 14, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $1,253M as of Mar 31, 2020
Annual revenue (TTM): $17.26M as of Mar 31, 2020
EBITDA (TTM): -$196.36M as of Mar 31, 2020
Net annual income (TTM): -$191.89M as of Mar 31, 2020
Free cash flow (TTM): -$199.51M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 101,061,195 as of Apr 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization